Physician

Daniel Joseph Allendorf, M.D.

According to 2025 Medicare claims, Daniel Allendorf, M.D. (NPI: 1073716163) practices medical oncology in the Birmingham, AL market, with the plurality of this provider's patient population coming from Shelby, AL. This provider's primary affiliated billing organization is BIRMINGHAM HEMATOLOGY ONCOLOGY ASSOC LLC (NPI: 1841216389; TIN: 522170293) and primary practice location at 35007-8703.

Allendorf's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 488 traditional Medicare patients, billed 157,159 HCPCS/CPT codes, and received $2,377,526 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,205 prescription claims across 358 beneficiaries totaling $3,737,801 in drug costs, led by Imbruvica (Ibrutinib). 2023 DME data shows 14 claims. Open Payments data shows 1 records totaling $27. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,291,993 to $3,737,801. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	584	260,499	$2,693,620
2016	535	231,065	$2,711,429
2017	462	151,405	$2,374,413
2018	560	214,002	$2,737,352
2019	657	238,986	$3,442,626
2020	562	188,625	$3,772,646
2021	563	139,725	$2,951,220
2022	509	196,369	$3,274,956
2023	477	179,880	$2,337,290
2024	488	157,159	$2,377,526

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	271	1,783	$1,291,993
2016	254	1,980	$1,814,641
2017	262	1,947	$1,713,538
2018	299	2,010	$2,673,385
2019	375	2,675	$4,275,677
2020	355	2,897	$5,873,511
2021	389	2,912	$6,097,028
2022	387	2,879	$6,715,191
2023	348	2,319	$4,101,774
2024	358	2,205	$3,737,801

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	193	$89,410
2016	16	181	$151,301
2017	11	80	$73,274
2018	11	115	$16,039
2019	N/R	115	$44,087
2020	N/R	62	$51,809
2021	N/R	16	$32,018
2022	N/R	13	$25,813
2023	N/R	14	$3,181
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	149	273	$85
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	337	627	$58
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	286	450	$12
36415	Insertion of needle into vein for collection of blood sample	448	1,264	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	423	1,285	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	64	1,834	$980,579
Revlimid	Lenalidomide	58	1,379	$863,177
Lenalidomide	Lenalidomide	32	770	$324,262
Tasigna	Nilotinib Hcl	19	532	$252,534
Calquence	Acalabrutinib Maleate	21	630	$240,502

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$27	Daiichi Sankyo Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Daniel Joseph Allendorf, M.D.?

Tedicare shows public-source Medicare data for Daniel Joseph Allendorf, M.D. (NPI 1073716163), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Daniel Joseph Allendorf, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Daniel Joseph Allendorf, M.D.?

Daniel Joseph Allendorf, M.D. is linked to BIRMINGHAM HEMATOLOGY ONCOLOGY ASSOC LLC (billing NPI 1841216389) in the available physician profile data.

Does Daniel Joseph Allendorf, M.D. have Open Payments data?

Daniel Joseph Allendorf, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.